8 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 14 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 8, Active not recruiting 2, Recruiting 2, Terminated 2 |
| Phase 2 | 7 | Active not recruiting 2, Completed 2, Recruiting 2, Terminated 1 |
Follow AC220: new trials by email Literature Review of AC220 trials Research Report on AC220
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Azacitidine, Quizartinib - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2020-07-21 | 2026-10-05 |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib - Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 52 | 2020-05-27 | 2026-06-02 |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cladribine, Cytarabine, Idarubicin - Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2019-10-22 | 2026-06-12 |
| Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Quizartinib, Venetoclax - Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2019-01-25 | 2024-09-19 |
| Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Quizartinib, Milademetan - Acute Myeloid Leukemia | Phase 1 | Terminated | Daiichi Sankyo | 10 | 2018-12-12 | 2022-05-20 |
| Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Quizartinib - Acute Myeloid Leukemia (AML) | Phase 1 | Completed | Daiichi Sankyo Co., Ltd. | 7 | 2018-11-05 | 2022-07-29 |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Decitabine, Quizartinib, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 73 | 2018-10-31 | 2026-09-24 |
| Phase 1 Study of Quizartinib AC220 - Relapsed AML, Refractory AML | Phase 1 | Completed | Daiichi Sankyo Co., Ltd. | 17 | 2016-02-01 | 2019-02-12 |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, Cytarabine, Quizartinib - FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 73 | 2013-11-12 | 2026-10-23 |
| A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) AC220 - Leukemia, Myeloid, Acute | Phase 1 | Completed | Daiichi Sankyo | 13 | 2012-04-01 | 2019-02-12 |
| A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) AC220, daunorubicin, cytarabine - Leukemia, Myeloid, Acute | Phase 1 | Completed | Daiichi Sankyo | 19 | 2011-10-01 | 2019-02-12 |
| AC220 for Children With Relapsed/Refractory ALL or AML AC220, Cytarabine, Etoposide - Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood | Phase 1 | Completed | Therapeutic Advances in Childhood Leukemia Consortium | 24 | 2011-09-01 | 2022-04-04 |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. Plerixafor, AC220, Ganetespib - Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Cardiff University | 113 | 2011-04-01 | 2014-06-11 |
| A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status AC220 - Acute Myeloid Leukemia, Leukemia | Phase 1 | Completed | Daiichi Sankyo | 76 | 2007-01-01 | 2020-05-11 |
Leukemia, Myeloid, Acute (12) · Myelodysplastic Syndromes (5) · Leukemia (3) · Recurrence (3) · Leukemia, Myelomonocytic, Chronic (2) · Aortic aneurysm, familial thoracic 4 (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Myeloid (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
M.D. Anderson Cancer Center (6) · Daiichi Sankyo (4) · Daiichi Sankyo Co., Ltd. (2) · Cardiff University (1) · Therapeutic Advances in Childhood Leukemia Consortium (1)
United States (11) · China (1) · Georgia (1) · Japan (1) · United Kingdom (1)
Musa Yilmaz (3) · Guy Gammon, MB, BS, MRCP (2) · Alan K Burnett (1) · Guillermo M Bravo (1) · Naval G Daver (1) · Nigel H Russell (1) · Todd Cooper, MD (1) · Yesid Alvarado, MD (1)
PMID 24002496, PMID 26920889, PMID 31359361, PMID 33208914, PMID 38744144, PMID 40327322